| Not Yet Recruiting | A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Trea NCT03468556 | Sinew Pharma Inc. | Phase 2 |
| Withdrawn | Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD NCT06352177 | Milton S. Hershey Medical Center | N/A |
| Recruiting | a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Pa NCT07128797 | Tasly Biopharmaceuticals Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS) NCT06623084 | Stefania Basili | — |
| Recruiting | A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH NCT06528314 | Akero Therapeutics, Inc | Phase 3 |
| Completed | Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With NCT06195943 | Milton S. Hershey Medical Center | N/A |
| Unknown | Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test NCT05108415 | HBI Solutions Inc. | — |
| Active Not Recruiting | Statins for the Treatment of NASH NCT04679376 | Mayo Clinic | Phase 2 |
| Unknown | Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement NCT04781933 | Mativa-Tech SA | N/A |
| Enrolling By Invitation | Semaglutide vs Sitagliptin NCT05195944 | University Health Network, Toronto | Phase 4 |
| Active Not Recruiting | The Franciscus Obesity NASH Study NCT05499949 | Franciscus Gasthuis | — |
| Unknown | Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH NCT05120557 | E-Scopics | N/A |
| Completed | The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease NCT05364684 | Massachusetts General Hospital | Phase 2 |
| Completed | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Co NCT05232071 | Inventiva Pharma | Phase 2 |
| Completed | DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally NCT05415722 | Terns, Inc. | Phase 2 |
| Unknown | A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D a NCT03970031 | Cirius Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | Nonalcoholic Fatty Liver Disease in HIV Database NCT05023044 | Johns Hopkins University | — |
| Recruiting | Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity NCT04232566 | Mayo Clinic | — |
| Completed | Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis NCT05284448 | Al-Azhar University | Phase 3 |
| Active Not Recruiting | Novel MRE Technique to Assess a Risk Factor for Liver Cancer NCT05165446 | Natalie Torok | — |
| Recruiting | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) NCT04697810 | Can-Fite BioPharma | Phase 2 |
| Unknown | Characterization of the Platelet Inflammatory Response in NAFL and NASH NCT05128253 | Stefania Basili | — |
| Recruiting | Estrogen Administration for the Treatment of NASH in Postmenopausal Women NCT04833140 | Massachusetts General Hospital | Phase 3 |
| Completed | A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia NCT05090111 | Aligos Therapeutics | Phase 1 |
| Unknown | Phase 2a Study of HPG1860 in Subjects With NASH NCT05338034 | Hepagene (Shanghai) Co., Ltd. | Phase 2 |
| Enrolling By Invitation | Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach NCT04841057 | University of Missouri-Columbia | N/A |
| Unknown | Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty NCT04976283 | Getz Pharma | Phase 4 |
| Completed | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers NCT04972396 | Altimmune, Inc. | Phase 1 |
| Active Not Recruiting | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Ad NCT04849728 | Inventiva Pharma | Phase 3 |
| Completed | PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis NCT05022693 | 89bio, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Sym NCT05039450 | Akero Therapeutics, Inc | Phase 2 |
| Completed | A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subje NCT04808154 | Sinew Pharma Inc. | Phase 1 |
| Recruiting | Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis NCT03587831 | University of Minnesota | N/A |
| Completed | Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoh NCT04929483 | 89bio, Inc. | Phase 2 |
| Not Yet Recruiting | THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) NCT04925362 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Pat NCT04897594 | Terns, Inc. | Phase 1 |
| Unknown | Gut Permeability and Bariatric-metabolic Surgery NCT05257200 | Medical University of Vienna | — |
| Completed | Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers NCT04874233 | Rivus Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease NCT04576923 | Indiana University | N/A |
| Unknown | Plant Stanols and Liver Inflammation in Overweight and Obese Children NCT04783116 | Maastricht University Medical Center | N/A |
| Completed | Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. NCT05441904 | Poxel SA | Phase 1 |
| Completed | Study to Evaluate MET642 in Patients With NASH NCT04773964 | Metacrine, Inc. | Phase 2 |
| Withdrawn | Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH NCT03538236 | Johns Hopkins University | N/A |
| Completed | Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE NCT04591106 | University of California, Los Angeles | — |
| Completed | Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Li NCT04616664 | University Hospital, Lille | — |
| Completed | A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis ( NCT04767529 | Akero Therapeutics, Inc | Phase 2 |
| Completed | Multiple Ascending Dose Study of HU6 in High BMI Volunteers NCT04709913 | Rivus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Liquid Biopsy for NASH and Liver Fibrosis NCT04677101 | Catholic University of the Sacred Heart | — |
| Unknown | Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH NCT04702490 | Metacrine, Inc. | Phase 2 |
| Withdrawn | Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism NCT04395950 | Columbia University | Phase 1 |
| Completed | A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis ( NCT04618744 | Oramed, Ltd. | Phase 2 |
| Unknown | NASH in Subjects With Different Classes of Obesity NCT04653103 | Catholic University of the Sacred Heart | — |
| Completed | A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial NCT04685993 | Lipocine Inc. | Phase 2 |
| Completed | Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) NCT04321343 | Poxel SA | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cir NCT04383951 | Indiana University | N/A |
| Completed | Ascending Dose Study of HU6 in Healthy Volunteers NCT04463017 | Rivus Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Non-Invasive Quantification of Liver Health in NASH (N-QUAN) NCT04054310 | Perspectum | N/A |
| Active Not Recruiting | Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects NCT04505436 | Hanmi Pharmaceutical Company Limited | Phase 2 |
| Terminated | Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrho NCT04365868 | Galectin Therapeutics Inc. | Phase 2 / Phase 3 |
| Completed | A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects NCT04480710 | Hepion Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Evaluation of an Endoscopic Sutured Gastroplasty in Patients With NonAlcoholic Steatohepatitis (NASH) and Fibr NCT04653311 | Erasme University Hospital | N/A |
| Completed | LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirr NCT04328077 | Terns, Inc. | Phase 2 |
| Unknown | Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment NCT04308980 | Russian Academy of Medical Sciences | Phase 2 / Phase 3 |
| Unknown | Effects of Plant Sterols and Stanols on Liver Inflammation NCT05037890 | Maastricht University Medical Center | N/A |
| Unknown | Bariatric Surgery vs. Lifestyle Modification for NASH NCT04298736 | Hospital de Clinicas de Porto Alegre | N/A |
| Unknown | NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL) NCT03968354 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat NCT04240145 | Gehad Abd Elaziz Mhmoud Ahmad | — |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects NCT04146805 | Blade Therapeutics | Phase 1 |
| Completed | Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients NCT04561895 | Cairo University | — |
| Withdrawn | Curcumin for Pediatric Nonalcoholic Fatty Liver Disease NCT04109742 | Columbia University | Phase 2 |
| Completed | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH NCT04173065 | Viking Therapeutics, Inc. | Phase 2 |
| Withdrawn | NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Rev NCT03864835 | Milton S. Hershey Medical Center | N/A |
| Active Not Recruiting | Tocotrienol Against the Progression of End Stage Liver Disease NCT02581085 | Chandan Sen | Phase 2 |
| Terminated | Vitamin E for NASH Treatment in HIV Infected Individuals NCT03669133 | Indiana University School of Medicine | Phase 2 |
| Active Not Recruiting | LITMUS Imaging Study NCT05479721 | University of Oxford | — |
| Recruiting | PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies NCT04371042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) NCT03648554 | Central Hospital, Nancy, France | Phase 4 |
| Active Not Recruiting | Hepatic Energy Fluxes in NASH and NAS Patients NCT03997422 | University of Minnesota | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic NCT03976687 | Enyo Pharma | Phase 1 |
| Completed | A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) NCT03976401 | Akero Therapeutics, Inc | Phase 2 |
| Completed | Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver NCT03897218 | RWTH Aachen University | N/A |
| Completed | Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo NCT03912532 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients NCT03963921 | Cellaion SA | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosi NCT03900429 | Madrigal Pharmaceuticals, Inc. | Phase 3 |
| Unknown | Hepaxa Management of Non-alcoholic Fatty Liver Disease NCT03801577 | BASF AS | N/A |
| Completed | Spironolactone Therapy In Young Women With NASH NCT03576755 | University of California, San Francisco | Phase 1 / Phase 2 |
| Unknown | Omega-3 vs Very Low Calorie Diet for Liver Size Reduction NCT03132662 | McMaster University | N/A |
| Unknown | Mechanism of DCs Dysfunction in Chronic HBV Infection NCT03753308 | University Hospital, Grenoble | — |
| Completed | Splanchnic and Systemic VLDL-TG and FFA Balance NCT04292977 | University of Aarhus | — |
| Completed | A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Popula NCT03726827 | Fatty liver Foundation | — |
| Completed | Effects of Exercise on VLDL-TG Metabolism NCT03678727 | University of Aarhus | — |
| Completed | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined NCT03783897 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in NCT04643795 | Madrigal Pharmaceuticals, Inc. | Phase 1 |
| Completed | Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects NCT03748628 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis NCT04066400 | Johannes Gutenberg University Mainz | N/A |
| Completed | Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers NCT03610945 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Terminated | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation NCT03534141 | University of California, San Francisco | N/A |
| Recruiting | A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver NCT03472157 | University Hospital, Lille | N/A |
| Completed | The Liver in the World Trade Center Health Program General Responder Cohort and Controls NCT03858920 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials NCT03611101 | Meridian Bioscience, Inc. | — |
| Terminated | A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) NCT03551522 | Gilead Sciences | Phase 2 |
| Completed | Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH NCT03490370 | NHS Tayside | N/A |
| Completed | Study of Gemcabene in Adults With FPLD NCT03508687 | Elif Oral | Phase 1 / Phase 2 |
| Terminated | The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Phy NCT03294941 | HepQuant, LLC | Phase 2 |
| Terminated | Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and NCT03332940 | Navidea Biopharmaceuticals | Phase 1 |
| Withdrawn | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM NCT03291249 | Tiziana Life Sciences LTD | Phase 2 |
| Completed | Effect of DMR in the Treatment of NASH NCT03536650 | Erasme University Hospital | N/A |
| Completed | Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan NCT03289897 | Perspectum | N/A |
| Terminated | An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD NCT03868566 | Sinew Pharma Inc. | Phase 2 |
| Completed | Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers NCT03213145 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH NCT02784444 | Cirius Therapeutics, Inc. | Phase 2 |
| Completed | Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 NCT03439189 | Meridian Bioscience, Inc. | — |
| Recruiting | The European NAFLD Registry NCT04442334 | Newcastle University | — |
| Suspended | Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study NCT04306939 | University of Pittsburgh | — |
| Enrolling By Invitation | Disease Prevention in Clinical Practice Base on Patient Specific Physiology NCT03308773 | Pacific Coast Family Medical Group | — |
| Terminated | Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocyto NCT00678587 | GlaxoSmithKline | Phase 3 |